| 1 | Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2 | 2026 | 23.8 | 29 | Citations (PDF) |
| 2 | First-Line Aumolertinib (EGFR Tyrosine Kinase Inhibitor) Plus Apatinib (VEGFR Inhibitor) Versus Aumolertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients: A Randomized, Multicenter, Phase II Trial | 2026 | 69.1 | 0 | Citations (PDF) |
| 3 | CACA Guidelines for Holistic Integrative Management of Older Adults With Cancer | 2026 | 1.8 | 2 | Citations (PDF) |
| 4 | Aumolertinib With Carboplatin–Pemetrexed Versus Aumolertinib for Nonsmall Cell Lung Cancer With EGFR and Concomitant Tumor Suppressor Genes (ACROSS2): An Open-Label, Multicenter, Randomized Phase 3 Study | 2026 | 651.5 | 8 | Citations (PDF) |
| 5 | Gotistobart or Docetaxel in Metastatic Squamous Non-Small Cell Lung Cancer: Stage 1 of the Randomized Phase 3 PRESERVE-003 Trial | 2026 | 51.2 | 2 | Citations (PDF) |
| 6 | Real-World Serplulimab Plus Chemotherapy for Extensive-Stage Small Cell Lung Cancer in China: An External Validation of ASTRUM-005 Trial | 2026 | 9.1 | 1 | Citations (PDF) |
| 7 | Oral KRAS G12D Inhibitor GFH375 for Previously Treated Advanced Solid Tumors With KRASG12D Mutations: A Phase 1 Trial. | 2026 | 51.2 | 1 | Citations (PDF) |
| 8 | A Plain Language Summary of Results From the CHOICE-01 Trial of Toripalimab Plus Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) | 2025 | 3.1 | 0 | Citations (PDF) |
| 9 | Glecirasib in KRASG12C-Mutated Nonsmall-Cell Lung Cancer: A Phase 2b Trial | 2025 | 51.2 | 44 | Citations (PDF) |
| 10 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Socazolimab or Placebo Combined With Carboplatin and Etoposide in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer | 2025 | 69.1 | 17 | Citations (PDF) |
| 11 | A B7H3-Targeting Antibody–Drug Conjugate in Advanced Solid Tumors: A Phase 1/1b Trial | 2025 | 51.2 | 124 | Citations (PDF) |
| 12 | Efficacy and Safety of Dacomitinib in Treatment-Naïve Patients With Advanced NSCLC and Brain Metastasis: A Multicenter Cohort Study | 2025 | 5.0 | 2 | Citations (PDF) |
| 13 | Potential Biomarkers of Primary Resistance to First- and Second-Generation EGFR-TKIs in Non-Small-Cell Lung Cancer: A Real-World Study | 2025 | 4.2 | 2 | Citations (PDF) |
| 14 | Harnessing Local and System Immune Profiling Delineating Differential Responders to First-Line Sintilimab (Anti-PD-1 Antibody) Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer: An Exploratory Biomarker Analysis of a Phase II Study | 2025 | 69.1 | 10 | Citations (PDF) |
| 15 | First-Line Serplulimab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: Updated Results and Biomarker Analysis From the ASTRUM-005 Randomized Clinical Trial | 2025 | 16.7 | 26 | Citations (PDF) |
| 16 | Immune Checkpoint Inhibitor-Based Therapy as the First-Line Treatment for Advanced Non-Small Cell Lung Cancer: Efficacy, Challenges, and Future Perspectives | 2025 | 2.9 | 9 | Citations (PDF) |
| 17 | Expert Consensus on the Diagnosis and Treatment of Malignant Mesothelioma of the Tunica Vaginalis Testis | 2025 | 0.0 | 3 | Citations (PDF) |
| 18 | First-Line Sacituzumab Tirumotecan With Tagitanlimab in Advanced Non-Small-Cell Lung Cancer: A Phase 2 Trial | 2025 | 51.2 | 25 | Citations (PDF) |
| 19 | Efficacy and Safety of Glecirasib in Solid Tumors With KRAS G12C Mutation: A Pooled Analysis of Two Phase I/II Trials | 2025 | 16.7 | 16 | Citations (PDF) |
| 20 | PACIFIC-5: A Phase III Clinical Trial of Consolidation Durvalumab in Patients With Unresectable Stage III NSCLC and No Progression After Concurrent or Sequential Chemoradiotherapy | 2025 | 44.4 | 18 | Citations (PDF) |
| 21 | A Phase Ib/II Study of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Plus Anlotinib as First-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer | 2024 | 8.1 | 46 | Citations (PDF) |
| 22 | Camrelizumab Combined With Apatinib and Nanoparticle Albumin-Bound Paclitaxel in Lung Adenocarcinoma (CAPAP-Lung): A Single-Arm Phase II Study | 2024 | 13.5 | 10 | Citations (PDF) |
| 23 | Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722 | 2024 | 23.8 | 175 | Citations (PDF) |
| 24 | Long-Term Survival of a Patient With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer (NSCLC) and Untreated Multiple Brain Metastases Treated With Zorifertinib: A Case Report | 2024 | 2.9 | 1 | Citations (PDF) |
| 25 | Vebreltinib for Advanced Non–Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study | 2024 | 23.8 | 48 | Citations (PDF) |
| 26 | Sintilimab in Combination With Stereotactic Body Radiotherapy and Granulocyte-Macrophage Colony-Stimulating Factor in Metastatic Non-Small Cell Lung Cancer: The Multicenter SWORD Phase 2 Trial | 2024 | 18.1 | 25 | Citations (PDF) |
| 27 | Phase Ib/II Study on the Safety, Tolerability, and Preliminary Efficacy of Pegylated Irinotecan (JK1201I) as Second-Line Monotherapy for Patients With Small-Cell Lung Cancer | 2024 | 3.8 | 2 | Citations (PDF) |
| 28 | Efficacy in Patients With EGFR-Positive Non-Small-Cell Lung Cancer Treated With Dacomitinib Who Had Skin Adverse Events: Post Hoc Analyses From ARCHER 1050 | 2024 | 3.1 | 5 | Citations (PDF) |
| 29 | Toripalimab Plus Chemotherapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (CHOICE-01): Final OS and Biomarker Exploration of a Randomized, Double-Blind, Phase 3 Trial | 2024 | 69.1 | 35 | Citations (PDF) |
| 30 | Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01) | 2023 | 23.8 | 183 | Citations (PDF) |
| 31 | Rh-Endostatin Plus Camrelizumab and Chemotherapy in First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Multicenter Retrospective Study | 2023 | 3.8 | 18 | Citations (PDF) |
| 32 | Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion–Positive Non–Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial | 2023 | 3.8 | 11 | Citations (PDF) |
| 33 | First-Line Immunotherapy for Advanced Non-Small Cell Lung Cancer: Current Progress and Future Prospects | 2023 | 6.3 | 12 | Citations (PDF) |
| 34 | A Novel Third-Generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-Mutant Non–Small Cell Lung Cancer: A Multicenter Phase I/II Study | 2022 | 9.5 | 21 | Citations (PDF) |
| 35 | Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901) | 2022 | 5.0 | 13 | Citations (PDF) |
| 36 | Three-Year Follow-Up and Patient-Reported Outcomes From CheckMate 078: Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer | 2022 | 4.9 | 22 | Citations (PDF) |
| 37 | Genomic Correlates of Programmed Cell Death Ligand 1 (PD-L1) Expression in Chinese Lung Adenocarcinoma Patients | 2022 | 7.2 | 13 | Citations (PDF) |
| 38 | An Evaluation of Aumolertinib for the Treatment of EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer | 2022 | 3.5 | 22 | Citations (PDF) |
| 39 | Clinical and Genomic Features of Chinese Lung Cancer Patients With Germline Mutations | 2022 | 18.1 | 36 | Citations (PDF) |
| 40 | Anlotinib for Patients With Small Cell Lung Cancer and Baseline Liver Metastases: A Post Hoc Analysis of the ALTER 1202 Trial | 2022 | 3.8 | 22 | Citations (PDF) |
| 41 | The Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy or Anti-Angiogenic Therapy as a Second-Line or Later Treatment Option for Advanced Non-Small Cell Lung Cancer: A Retrospective Comparative Cohort Study | 2022 | 2.8 | 14 | Citations (PDF) |
| 42 | Sintilimab Versus Docetaxel as Second-Line Treatment in Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer: An Open-Label, Randomized Controlled Phase 3 Trial (ORIENT-3) | 2022 | 16.7 | 59 | Citations (PDF) |
| 43 | Dacomitinib Induces Objective Responses in Metastatic Brain Lesions of Patients With EGFR-Mutant Non-Small-Cell Lung Cancer: A Brief Report | 2021 | 4.9 | 31 | Citations (PDF) |
| 44 | Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. | 2021 | 23.8 | 258 | Citations (PDF) |
| 45 | Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer: 2-Year Follow-Up From a Randomized, Open-Label, Phase 3 Study (CheckMate 078) | 2021 | 4.9 | 57 | Citations (PDF) |
| 46 | Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers | 2021 | 6.9 | 3 | Citations (PDF) |
| 47 | Prediction of Egfr Mutation Status in Lung Adenocarcinoma Using Multi-Source Feature Representations | 2021 | | 7 | Citations (PDF) |
| 48 | Efficacy, Safety, and Genetic Analysis of Furmonertinib (AST2818) in Patients With EGFR T790M Mutated Non-Small-Cell Lung Cancer: A Phase 2b, Multicentre, Single-Arm, Open-Label Study | 2021 | 28.0 | 107 | Citations (PDF) |
| 49 | Icotinib Versus Chemotherapy as Adjuvant Treatment for Stage II–IIIA EGFR-Mutant Non-Small-Cell Lung Cancer (EVIDENCE): A Randomised, Open-Label, Phase 3 Trial | 2021 | 28.0 | 173 | Citations (PDF) |
| 50 | Sintilimab, Stereotactic Body Radiotherapy and Granulocyte–Macrophage Colony Stimulating Factor as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer: Safety Run-In Results of a Multicenter, Single-Arm, Phase II Trial | 2021 | 3.9 | 23 | Citations (PDF) |
| 51 | Next-Generation Sequencing Assisted Diagnosis of Cervical Metastasis in EGFR-Mutated Lung Adenocarcinoma: A Case Report | 2021 | 2.9 | 4 | Citations (PDF) |
| 52 | Effectiveness of Anlotinib in Patients With Small-Cell Lung Cancer and Pleural Effusion: Subgroup Analysis From a Randomized, Multicenter, Phase II Study | 2021 | 2.9 | 9 | Citations (PDF) |
| 53 | Genomic Signatures Define Three Subtypes of EGFR-Mutant Stage II–III Non-Small-Cell Lung Cancer With Distinct Adjuvant Therapy Outcomes | 2021 | 18.1 | 74 | Citations (PDF) |
| 54 | Case Report: Tissue Origin Identification for Cancer of Unknown Primary: Gene Expression Profiling Approach | 2021 | 3.5 | 4 | Citations (PDF) |
| 55 | Disparity in Clinical Outcomes Between Pure and Combined Pulmonary Large-Cell Neuroendocrine Carcinoma: A Multi-Center Retrospective Study | 2020 | 4.9 | 44 | Citations (PDF) |
| 56 | Quality of Life With Adjuvant Gefitinib Versus Vinorelbine Plus Cisplatin in Patients With Completely Resected Stage II–IIIA (N1–N2) EGFR-Mutant Non-Small-Cell Lung Cancer: Results From the ADJUVANT (CTONG1104) Study | 2020 | 4.9 | 10 | Citations (PDF) |
| 57 | Silencing of Long Non-Coding RNA SOX21-AS1 Inhibits Lung Adenocarcinoma Invasion and Migration by Impairing TSPAN8 via Transcription Factor GATA6 | 2020 | 8.4 | 18 | Citations (PDF) |
| 58 | Real-World Scenario of Patients With Lung Cancer Amid the Coronavirus Disease 2019 Pandemic in the People’s Republic of China | 2020 | 3.0 | 16 | Citations (PDF) |
| 59 | Safety and Efficacy of Aprepitant as Mono and Combination Therapy for the Prevention of Emetogenic Chemotherapy-Induced Nausea and Vomiting: Post-Marketing Surveillance in China | 2020 | 1.3 | 7 | Citations (PDF) |
| 60 | Circulating Tumor DNA Clearance Predicts Prognosis Across Treatment Regimen in a Large Real-World Longitudinally Monitored Advanced Non-Small Cell Lung Cancer Cohort | 2020 | 2.8 | 93 | Citations (PDF) |
| 61 | Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation | 2020 | 15.0 | 100 | Citations (PDF) |
| 62 | Peripheral Blood Biomarkers Associated With Outcome in Non-Small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy | 2020 | 3.5 | 42 | Citations (PDF) |
| 63 | Abstract CT127: A Phase I Study of cMET Inhibitor Bozitinib in Patients With Advanced NSCLC Harboring cMET Alterations | 2020 | 11.8 | 20 | Citations (PDF) |
| 64 | The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104) | 2019 | 15.0 | 64 | Citations (PDF) |
| 65 | Irinotecan Plus S-1 Versus S-1 in Patients With Previously Treated Recurrent or Metastatic Esophageal Cancer (ESWN 01): A Prospective Randomized, Multicenter, Open-Labeled Phase 3 Trial | 2019 | 16.7 | 25 | Citations (PDF) |
| 66 | Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. | 2019 | 15.0 | 337 | Citations (PDF) |
| 67 | The Impact of Previous Therapy Strategy on the Efficiency of Anlotinib Hydrochloride as a Third-Line Treatment on Patients With Advanced Non-Small Cell Lung Cancer (NSCLC): A Subgroup Analysis of ALTER0303 Trial | 2019 | 2.8 | 32 | Citations (PDF) |
| 68 | Population Pharmacokinetics and Individualized Lobaplatin Regimen for the Treatment of Chinese Small Cell Lung Cancer in the Elderly | 2019 | 2.2 | 0 | Citations (PDF) |
| 69 | Association of microRNA-423 rs6505162 C>A Polymorphism With Susceptibility and Metastasis of Colorectal Carcinoma | 2018 | 2.2 | 17 | Citations (PDF) |
| 70 | Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II–IIIA (N1–N2) EGFR-Mutant NSCLC (Adjuvant/CTONG1104): A Randomised, Open-Label, Phase 3 Study | 2018 | 28.5 | 503 | Citations (PDF) |
| 71 | Immunotherapy for Non-Small Cell Lung Cancers: Biomarkers for Predicting Responses and Strategies to Overcome Resistance | 2018 | 4.3 | 49 | Citations (PDF) |
| 72 | Clinical Characterization of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes Responding to Afatinib in Chinese Lung Cancer Patients | 2018 | 2.6 | 33 | Citations (PDF) |
| 73 | Patient-Derived Tumor Immune Microenvironments in Patient-Derived Xenografts of Lung Cancer | 2018 | 9.4 | 14 | Citations (PDF) |
| 74 | Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial | 2018 | 19.8 | 583 | Citations (PDF) |
| 75 | A Consensus on Immunotherapy From the 2017 Chinese Lung Cancer Summit Expert Panel | 2018 | 2.8 | 9 | Citations (PDF) |
| 76 | Adenocarcinoma of the Lung With EGFR Gene Mutation and Subsequent Resistance Mechanisms Exploration: Case Report | 2017 | 2.6 | 1 | Citations (PDF) |
| 77 | miR‑96 Induces Cisplatin Chemoresistance in Non‑Small Cell Lung Cancer Cells by Downregulating SAMD9 | 2016 | 2.4 | 61 | Citations (PDF) |
| 78 | Effect of Transporter and DNA Repair Gene Polymorphisms to Lung Cancer Chemotherapy Toxicity | 2016 | 3.4 | 18 | Citations (PDF) |
| 79 | Mefunidone Attenuates Tubulointerstitial Fibrosis in a Rat Model of Unilateral Ureteral Obstruction | 2015 | 3.2 | 28 | Citations (PDF) |
| 80 | Fluorofenidone Offers Improved Renoprotection at Early Interventions During the Course of Diabetic Nephropathy in Db/Db Mice via Multiple Pathways | 2014 | 3.2 | 10 | Citations (PDF) |